HIND
Vyome Holdings, Inc.
There isn't enough reported data to score HIND yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HIND Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
HIND's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIND PE Valuation
HIND has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HIND Forward outlook
There aren't enough analyst estimates for HIND to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HIND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$226,722.00 | +$953,578.00 |
| Q2 2023 | -$371,606.00 | +$1,087,094.00 |
| Q1 2023 | -$510,342.00 | +$939,658.00 |
| Q4 2022 | -$628,894.00 | +$1,076,306.00 |
| Q3 2022 | -$1,180,300.00 | -$84,100.00 |
| Q2 2022 | -$1,458,700.00 | -$617,700.00 |
| Q1 2022 | -$1,450,000.00 | -$275,500.00 |
| Q4 2021 | -$1,705,200.00 | -$321,900.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 100% for HIND versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
HIND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $58K | +67% |
| Q2 2026 | $27K | -98% |
| Q1 2026 | $31.6K | -97% |
| Q4 2025 | $36.6K | -98% |
| Q3 2025 | $34.6K | -98% |
| Q2 2025 | $1.2M | -37% |
| Q1 2025 | $1.1M | -43% |
| Q4 2024 | $1.8M | -8.9% |
HIND's revenue is recovering but still below its 2021 peak: $57,998 last quarter, up 67% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1761% | +23001 points |
| Q2 2026 | -3200% | -2978 points |
| Q1 2026 | -3577% | -3379 points |
| Q4 2025 | -3707% | -3613 points |
| Q3 2025 | -24762% | -24685 points |
| Q2 2025 | -222% | -118 points |
| Q1 2025 | -198% | -85 points |
| Q4 2024 | -94% | +1.3 points |
HIND's operating margin was −1761% last quarter, up 23001 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HIND on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HIND on profitability, with a higher operating margin.
HIND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$627.6K | -114% |
| Q2 2026 | -$903.7K | +$3.6M |
| Q1 2026 | -$1.4M | +$683K |
| Q4 2023 | -$2.5M | +$452K |
| Q3 2023 | -$2.8M | +$2.5M |
| Q2 2023 | -$6.7M | -$264K |
| Q1 2023 | -$5.1M | +$2.3M |
| Q4 2022 | -$2.9M | +$584K |
HIND has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HIND on cash generation, producing positive trailing cash flow while its opponent burns cash.
HIND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +67 shares |
| 1 year | +767% | +4.6K shares |
| 3 years | +18314% | +5.1K shares |
HIND has 5,156 diluted shares, up 767% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HIND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HIND Net Leverage
HIND's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HIND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 12.6 | Oversold |
HIND's weekly RSI is 28 (oversold) and its Stochastic is 13 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HIND PE vs Healthcare Sector
HIND has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HIND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 11% below |
| 20 week MA | $2.04 | 20% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $47.1 | 97% below |
| 200 week MA | $3,472.6 | 100% below |
HIND is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HIND on trend strength, trading above more of its moving averages.
HIND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,644,300.0 | $1,383,300.0 | -16% |
| 2021 | $1,383,300.0 | $574,200.0 | -58% |
| 2022 | $574,200.0 | $35,612.0 | -94% |
| 2023 | $35,612.0 | $1,450.0 | -96% |
| 2024 | $1,450.0 | $455.0 | -69% |
| 2025 | $455.0 | $3.73 | -99% |
| 2026 YTD | $3.73 | $1.63 | -56% |
HIND has finished every year since 2020 lower, and it's down 56% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HIND on returns for 2026, with the stronger performance.